About Athersys (NASDAQ:ATHX)
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ATHX
- CUSIP: N/A
- Web: www.athersys.com
Capitalization:- Market Cap: $233.52 million
- Outstanding Shares: 113,911,000
Average Prices:- 50 Day Moving Avg: $2.17
- 200 Day Moving Avg: $1.69
- 52 Week Range: $1.02 - $2.63
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.83
- P/E Growth: -0.34
Sales & Book Value:- Annual Revenue: $3.43 million
- Price / Sales: 68.08
- Book Value: $0.23 per share
- Price / Book: 8.91
Profitability:- EBITDA: ($27,300,000.00)
- Net Margins: -729.07%
- Return on Equity: -121.47%
- Return on Assets: -88.83%
Debt:- Current Ratio: 4.50%
- Quick Ratio: 4.50%
Misc:- Average Volume: 1.13 million shs.
- Beta: -0.15
- Short Ratio: 11.19
Frequently Asked Questions for Athersys (NASDAQ:ATHX)
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How were Athersys' earnings last quarter?
Athersys, Inc. (NASDAQ:ATHX) posted its earnings results on Wednesday, August, 9th. The company reported ($0.06) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.06). The firm had revenue of $0.67 million for the quarter, compared to analysts' expectations of $0.96 million. Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The company's quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the firm earned ($0.08) EPS. View Athersys' Earnings History.
When will Athersys make its next earnings announcement?
Where is Athersys' stock going? Where will Athersys' stock price be in 2017?
3 analysts have issued 1-year target prices for Athersys' shares. Their forecasts range from $7.00 to $12.00. On average, they expect Athersys' stock price to reach $9.50 in the next year. View Analyst Ratings for Athersys.
What are analysts saying about Athersys stock?
Here are some recent quotes from research analysts about Athersys stock:
- 1. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (10/10/2017)
- 2. Maxim Group analysts commented, "A negative blogger blasted Athersys Multistem with Zombie" like properties as a therapeutic that just won’t die. The article (in our opinion) picks and chooses elements of the Athersys story which when taken out of context paint a confusing picture." (10/5/2017)
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include Progenics Pharmaceuticals (PGNX), Atara Biotherapeutics (ATRA), Seres Therapeutics (MCRB), Mersana Therapeutics (MRSN), BioCryst Pharmaceuticals (BCRX), Merus N.V. (MRUS), GlycoMimetics (GLYC), Urogen Pharma (URGN), NantKwest (NK), Ra Pharmctl (RARX), CymaBay Therapeutics (CBAY), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals Holdings (CRBP), Bellicum Pharmaceuticals (BLCM), BioSpecifics Technologies Corp. (BSTC), Akebia Therapeutics (AKBA), Geron Corporation (GERN) and Edge Therapeutics (EDGE).
Who are Athersys' key executives?
Athersys' management team includes the folowing people:
- Gil Van Bokkelen Ph.D., Chairman of the Board, Chief Executive Officer
- William Lehmann Jr, President, Chief Operating Officer
- John J. Harrington Ph.D., Executive Vice President, Chief Scientific Officer, Director
- Robert J. Deans Ph.D., Executive Vice President - Regenerative Medicine
- Laura K. Campbell CPA, Vice President - Finance
- Lee E. Babiss Ph.D., Lead Independent Director
- Ismail Kola, Independent Director
- Lorin Jeffry Randall, Independent Director
- Jack L. Wyszomierski, Independent Director
How do I buy Athersys stock?
Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Athersys' stock price today?
One share of Athersys stock can currently be purchased for approximately $2.05.
MarketBeat Community Rating for Athersys (NASDAQ ATHX)MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Athersys (NASDAQ:ATHX)Earnings History by Quarter for Athersys (NASDAQ ATHX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.06) | | | | | N/A |  |
| 8/9/2017 | Q2 2017 | ($0.06) | ($0.06) | $0.96 million | $0.67 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.07) | ($0.06) | $0.45 million | $1.50 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.08) | ($0.10) | $0.45 million | $0.98 million | View | Listen | |
| 11/9/2016 | Q3 2016 | ($0.10) | ($0.07) | $0.60 million | $0.31 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.10) | ($0.08) | $0.32 million | $0.60 million | View | N/A | |
| 5/5/2016 | Q1 | ($0.08) | $0.06 | $1.85 million | $15.45 million | View | N/A | |
| 3/10/2016 | Q4 | ($0.09) | $0.04 | $3.72 million | $10.61 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.07) | ($0.08) | $1.75 million | $0.40 million | View | Listen | |
| 8/6/2015 | Q2 | ($0.08) | $0.02 | $2.66 million | $0.22 million | View | N/A | |
| 5/11/2015 | Q115 | ($0.07) | ($0.16) | $2.01 million | $0.73 million | View | Listen | |
| 3/12/2015 | Q414 | ($0.09) | ($0.08) | $0.50 million | $0.24 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.09) | ($0.11) | $0.54 million | $0.29 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.09) | ($0.06) | $0.70 million | $0.40 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.10) | ($0.09) | $0.66 million | $0.71 million | View | N/A | |
| 3/13/2014 | Q413 | ($0.11) | ($0.15) | $1.81 million | $0.92 million | View | N/A | |
| 11/14/2013 | Q3 | ($0.12) | ($0.10) | $0.49 million | $0.62 million | View | Listen | |
| 8/13/2013 | Q2 2013 | ($0.12) | ($0.11) | $390.00 million | $0.57 million | View | N/A | |
| 5/14/2013 | Q1 2013 | ($0.11) | ($0.18) | $1.58 million | $0.33 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.13) | ($0.12) | $2.51 million | $1.00 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Athersys (NASDAQ:ATHX)2017 EPS Consensus Estimate: ($0.27)
2018 EPS Consensus Estimate: ($0.42)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.07) | ($0.07) | ($0.07) |
| Q2 2017 | 2 | ($0.07) | ($0.06) | ($0.07) |
| Q3 2017 | 2 | ($0.07) | ($0.06) | ($0.07) |
| Q4 2017 | 2 | ($0.08) | ($0.06) | ($0.07) |
| Q1 2018 | 1 | ($0.09) | ($0.09) | ($0.09) |
| Q2 2018 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q3 2018 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q4 2018 | 1 | ($0.12) | ($0.12) | ($0.12) |
(Data provided by Zacks Investment Research)
Dividend History for Athersys (NASDAQ:ATHX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Athersys (NASDAQ:ATHX)Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 19.11%
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/19/2017 | William Lehmann Jr | Insider | Sell | 15,000 | $2.38 | $35,700.00 | |
| 9/18/2017 | John J Harrington | EVP | Sell | 15,000 | $2.17 | $32,550.00 | |
| 6/16/2017 | John J Harrington | EVP | Sell | 36,000 | $1.45 | $52,200.00 | |
| 2/1/2017 | Ismail Kola | Director | Buy | 15,000 | $1.01 | $15,150.00 | |
| 2/1/2017 | Laura K Campbell | Insider | Buy | 20,000 | $1.01 | $20,200.00 | |
| 12/19/2016 | William Lehmann Jr | Insider | Sell | 3,000 | $1.60 | $4,800.00 | |
| 12/16/2016 | John J Harrington | EVP | Sell | 15,000 | $1.60 | $24,000.00 | |
| 9/19/2016 | William Lehmann Jr | Insider | Sell | 3,000 | $1.96 | $5,880.00 | |
| 9/16/2016 | John J Harrington | EVP | Sell | 15,000 | $1.96 | $29,400.00 | |
| 6/21/2016 | William Lehmann Jr | COO | Sell | 25,000 | $2.17 | $54,250.00 | |
| 3/21/2016 | William Lehmann Jr | COO | Sell | 25,000 | $2.41 | $60,250.00 | |
| 12/21/2015 | William Lehmann, Jr. | COO | Sell | 25,000 | $1.03 | $25,750.00 | |
| 9/21/2015 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.36 | $12,920.00 | |
| 9/21/2015 | John J. Harrington | EVP | Sell | 8,150 | $1.36 | $11,084.00 | |
| 9/21/2015 | William Lehmann, Jr. | COO | Sell | 25,000 | $1.36 | $34,000.00 | |
| 6/22/2015 | William Lehmann Jr | COO | Sell | 25,000 | $1.21 | $30,250.00 | |
| 6/19/2015 | John J Harrington | Insider | Sell | 8,150 | $1.23 | $10,024.50 | |
| 6/19/2015 | Robert J Deans | EVP | Sell | 5,080 | $1.23 | $6,248.40 | |
| 6/9/2015 | Kenneth H Traub | Director | Buy | 30,000 | $1.27 | $38,100.00 | |
| 3/20/2015 | William Lehmann Jr | COO | Sell | 25,000 | $3.14 | $78,500.00 | |
| 3/19/2015 | Bokkelen Gil Van | CEO | Sell | 9,500 | $3.10 | $29,450.00 | |
| 3/19/2015 | Robert J Deans | EVP | Sell | 5,080 | $3.10 | $15,748.00 | |
| 12/19/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.29 | $12,255.00 | |
| 12/19/2014 | Robert J Deans | EVP | Sell | 5,080 | $1.28 | $6,502.40 | |
| 12/19/2014 | William Lehmann Jr | COO | Sell | 30,000 | $1.29 | $38,700.00 | |
| 9/24/2014 | Kenneth H Traub | Director | Buy | 30,000 | $1.39 | $41,700.00 | |
| 9/22/2014 | William Lehmann Jr | COO | Sell | 30,000 | $1.40 | $42,000.00 | |
| 9/19/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.41 | $13,395.00 | |
| 9/19/2014 | John J Harrington | Insider | Sell | 8,150 | $1.41 | $11,491.50 | |
| 9/19/2014 | Robert J Deans | EVP | Sell | 5,080 | $1.41 | $7,162.80 | |
| 8/18/2014 | Lorin Randall | Director | Sell | 15,000 | $1.54 | $23,100.00 | |
| 6/20/2014 | William Lehmann Jr | COO | Sell | 12,000 | $1.58 | $18,960.00 | |
| 6/19/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.63 | $15,485.00 | |
| 6/19/2014 | John J Harrington | Insider | Sell | 8,150 | $1.63 | $13,284.50 | |
| 6/19/2014 | Robert J Deans | EVP | Sell | 5,080 | $1.63 | $8,280.40 | |
| 6/19/2014 | William Lehmann Jr | COO | Sell | 13,000 | $1.62 | $21,060.00 | |
| 3/20/2014 | William Lehmann Jr | COO | Sell | 25,000 | $3.62 | $90,500.00 | |
| 3/18/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $3.54 | $33,630.00 | |
| 3/18/2014 | John J Harrington | Insider | Sell | 8,150 | $3.54 | $28,851.00 | |
| 3/18/2014 | Robert J Deans | EVP | Sell | 5,080 | $3.54 | $17,983.20 | |
| 12/20/2013 | William Lehmann Jr | COO | Sell | 25,000 | $2.13 | $53,250.00 | |
| 12/11/2013 | Kenneth H Traub | Director | Buy | 20,000 | $1.94 | $38,800.00 | |
| 9/20/2013 | John J Harrington | Insider | Sell | 30,000 | $1.82 | $54,600.00 | |
| 9/20/2013 | William Lehmann Jr | COO | Sell | 12,000 | $1.83 | $21,960.00 | |
| 11/28/2012 | Laura K Campbell | VP | Buy | 10,000 | $1.01 | $10,100.00 | |
| 11/15/2012 | Robert J Deans | EVP | Buy | 3,500 | $0.99 | $3,465.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Athersys (NASDAQ:ATHX)
Latest Headlines for Athersys (NASDAQ:ATHX)
| Source: |
|
| Date | Headline |
|---|
 | Bears On Parade - Regardless, Athersys Is Developing Key Relationships For A Successful Future
seekingalpha.com - October 14 at 2:43 AM |
 | Featured Company News - Athersys Signs Agreement with Nikon CeLL Innovation for Commercial Manufacturing of MultiStem in Japan
finance.yahoo.com - October 13 at 4:39 PM |
| Athersys Partners Up: Can Nikon CeLL Get MultiStem On Track? - Seeking Alpha
seekingalpha.com - October 13 at 2:58 AM |
 | Athersys (ATHX) in Focus: Stock Moves 7.2% Higher - Nasdaq
www.nasdaq.com - October 13 at 2:58 AM |
| Athersys (ATHX) in Focus: Stock Moves 7.2% Higher
finance.yahoo.com - October 12 at 4:57 PM |
 | Athersys Hikes on MultiStem Hookup with Japanese Firm
www.baystreet.ca - October 11 at 5:41 PM |
 | Athersys (ATHX) Reports Collaboration Agreement with Nikon Cell Innovation Co. on MultiStem Commercial Manufacturing in Japan
www.streetinsider.com - October 11 at 5:41 PM |
| Athersys and Nikon CeLL Innovation to Collaborate on MultiStem® Commercial Manufacturing in Japan
finance.yahoo.com - October 11 at 5:41 PM |
 | Athersys, Inc. (ATHX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 10 at 5:46 PM |
| Mid-Day Market Update: Crude Oil Up 2.7%; MannKind Shares Spike Higher
www.nasdaq.com - October 10 at 5:25 PM |
 | Athersys to Host Third Quarter Financial Results Call
feeds.benzinga.com - October 9 at 11:35 AM |
| Athersys (ATHX) & Its Rivals Head to Head Survey
www.americanbankingnews.com - October 8 at 9:00 AM |
| William Blair Weighs in on Athersys, Inc.'s Q1 2018 Earnings (ATHX)
www.americanbankingnews.com - October 6 at 11:04 AM |
| 3 Things In Biotech You Should Learn Today: October 6, 2017
seekingalpha.com - October 6 at 9:07 AM |
| Maxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target
www.americanbankingnews.com - October 5 at 9:30 PM |
| Maxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target
www.americanbankingnews.com - October 5 at 9:30 PM |
| Athersys (ATHX) Announces RMAT Designation From FDA - StreetInsider.com
www.streetinsider.com - October 5 at 7:01 PM |
| Athersys: Cash Concerns Cast A Long Shadow - Seeking Alpha
seekingalpha.com - September 28 at 4:33 PM |
| Insider Selling: Athersys, Inc. (ATHX) EVP Sells 15,000 Shares of Stock
www.americanbankingnews.com - September 19 at 8:32 PM |
| Athersys, Inc. (ATHX) Insider William Lehmann, Jr. Sells 15,000 Shares
www.americanbankingnews.com - September 19 at 8:32 PM |
| Regulatory Alignment Reinforces Bullish Case For Athersys - Seeking Alpha
seekingalpha.com - September 19 at 4:09 PM |
| Athersys Multistem Partner Healios KK Delays Implementation Of Critical Phase III TREASURE Trial - Seeking Alpha
seekingalpha.com - September 11 at 4:12 PM |
| Athersys (ATHX) in Focus: Stock Moves 10.22% Higher - Nasdaq
www.nasdaq.com - September 8 at 2:12 AM |
| Athersys, Inc. (ATHX) Given Buy Rating at Maxim Group
www.americanbankingnews.com - September 4 at 2:32 PM |
| Athersys, Inc. to Post Q4 2017 Earnings of ($0.08) Per Share, William Blair Forecasts (NASDAQ:ATHX)
www.americanbankingnews.com - August 14 at 6:42 AM |
| Athersys, Inc. (ATHX) Posts Earnings Results, Meets Estimates
www.americanbankingnews.com - August 10 at 3:42 PM |
| Edited Transcript of ATHX earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 3:35 PM |
 | Athersys Reports Second Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 4:20 PM |
| Featured Company News – Athersys Reported Alignment of Key Regulators for Pivotal Registration Study in Ischemic Stroke
finance.yahoo.com - August 9 at 4:20 PM |
| Investor Network: Athersys, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 4:19 PM |
| Athersys Reports Second Quarter 2017 Results
finance.yahoo.com - August 9 at 4:19 PM |
| Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke
finance.yahoo.com - August 7 at 4:56 PM |
| Maxim Group Analysts Give Athersys, Inc. (ATHX) a $9.00 Price Target
www.americanbankingnews.com - August 7 at 1:08 PM |
| Athersys, Inc. (ATHX) to Release Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:18 AM |
| Athersys's Cardiovascular Health Program Is Ambitious and Well-Calculated - Seeking Alpha
seekingalpha.com - July 28 at 10:22 PM |
| Athersys to Host Second Quarter Financial Results Call - GlobeNewswire (press release)
globenewswire.com - July 10 at 4:10 PM |
| Athersys to Host Second Quarter Financial Results Call
finance.yahoo.com - July 10 at 4:10 PM |
| Athersys, Inc. (NASDAQ:ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - July 10 at 2:30 PM |
| ETFs with exposure to Athersys, Inc. : July 7, 2017
finance.yahoo.com - July 8 at 7:02 AM |
| Athersys And Aurinia Target Human And Animal Health - Seeking Alpha
seekingalpha.com - June 27 at 3:50 PM |
| Why Athersys, Inc. (ATHX) Could Be Positioned for a Surge - Nasdaq
www.nasdaq.com - June 9 at 2:28 AM |
| Upcoming Short- And Long-Term Catalysts For Athersys - Seeking Alpha
seekingalpha.com - May 31 at 3:41 PM |
| Athersys Poised For Lucrative Stem Cell Stroke Partnership This Year
seekingalpha.com - May 16 at 12:30 PM |
| Athersys beats by $0.01, beats on revenue
seekingalpha.com - May 11 at 9:11 PM |
| Athersys: Initiating Coverage With Buy Rating And Price Target Of $8
seekingalpha.com - April 19 at 4:00 PM |
 | Here's What Might Be Pushing Up Shares of Athersys, Inc. Today
www.fool.com - March 31 at 3:49 PM |
 | Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
www.investopedia.com - March 29 at 8:53 PM |
| Athersys (ATHX) Says Two Publications Highlight MultiStem for Treating Ischemic Stroke
www.streetinsider.com - March 20 at 8:53 AM |
 | Two New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke
us.rd.yahoo.com - March 20 at 8:53 AM |
| 6:31 am Athersys announces that clinical investigators have published results from Athersys' Phase 2 trial of MultiStem cell therapy for treating ischemic stroke patients in the peer-reviewed journal The Lancet Neurology
us.rd.yahoo.com - March 20 at 8:53 AM |
Athersys (ATHX) Chart for Wednesday, October, 18, 2017
